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Abstract
Background: Large outbreaks of Lassa fever (LF) occur annually in Nigeria. The case fatality rate among hospitalised
cases is ~ 20%. The antiviral drug ribavirin along with supportive care and rehydration are the recommended
treatments but must be administered early (within 6 days of symptom onset) for optimal results. We aimed to
identify factors associated with late presentation of LF cases to a healthcare facility to inform interventions.
Methods: We undertook a retrospective cohort study of all laboratory confirmed LF cases reported in Nigeria from
December 2018 to April 2019. We performed descriptive epidemiology and a univariate Cox proportional-hazards
regression analysis to investigate the effect of clinical (symptom severity), epidemiological (age, sex, education,
occupation, residential State) and exposure (travel, attendance at funeral, exposure to rodents or confirmed case)
factors on time to presentation.
Results: Of 389 cases, median presentation time was 6 days (IQR 4–10 days), with 53% attending within 6 days.
There were no differences in presentation times by sex but differences were noted by age-group; 60+ year-olds
had the longest delays while 13–17 year-olds had the shortest. By sex and age, there were differences seen among
the younger ages, with 0–4-year-old females presenting earlier than males (4 days and 73% vs. 10 days and 30%).
For 5–12 and 13–17 year-olds, males presented sooner than females (males: 5 days, 65% and 3 days, 85% vs.
females: 6 days, 50% and 5 days, 61%, respectively). Presentation times differed across occupations 4.5–9 days and
20–60%, transporters (people who drive informal public transport vehicles) had the longest delays. Other data were
limited (41–95% missing). However, the Cox regression showed no factors were statistically associated with longer
presentation time.
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Conclusions: Whilst we observed important differences in presentation delays across factors, our sample size was
insufficient to show any statistically significant differences that might exist. However, almost half of cases presented
after 6 days of onset, highlighting the need for more accurate and complete surveillance data to determine if there
is a systemic or specific cause for delays, so to inform, monitor and evaluate public health strategies and improve
outcomes.
Keywords: Lassa fever, Nigeria, Surveillance, Epidemiology, Delayed presentation, Healthcare, Retrospective cohort
study
Background
Lassa fever (LF) infection is a viral haemorrhagic fever
(VHF) caused by a single stranded RNA virus belonging
to the genus Mammarenavirus. Lassa mammarenavirus
is transmitted to humans via contact with food or house-
hold items contaminated with rodent urine or faeces,
particularly a rodent of the genus Mastomys, commonly
known as the multimammate rat. Lassa mammarena-
virus may also be spread between humans through direct
contact with the blood, urine, faeces, or other bodily se-
cretions of an infected person [1, 2]. However, secondary
attack rates are generally less than 5% [1–3].
Lassa fever is endemic in Nigeria, with a seasonal pat-
tern, peaking in the dry season (November to April) [3].
Recent years have seen an increase in the incidence of
LF reported in Nigeria [3, 4]. Between January and May
2019, there were 578 confirmed cases in 21 states with a
case fatality rate of approximately 22%, surpassing the
total case counts in 2017 and 2018 [5–7].
The incubation period of LF ranges from 2 to 21 days
[2]. The onset of the disease, when symptomatic, is usu-
ally gradual, starting with non-specific symptoms then
developing to more severe symptoms (including haemor-
rhage) after a week or so. The case fatality rate (CFR)
among hospitalised cases is approximately 20%, but mild
or asymptomatic infection is common [1–3].
Early treatment is considered vital in LF and delays in
presentation to healthcare facilities may impact survival.
Current recommended treatment is largely supportive
(rehydration and symptomatic treatment). Although
controversy exists over its efficacy, intravenous adminis-
tration of the antiviral drug ribavirin has long been con-
sidered the standard of care, with one study showing the
most impact on survival if given within the first 6 days
after symptom onset [1–3, 8–10].
Investigation of the 2018–19 LF outbreak in Nigeria
showed a higher CFR among people presenting later to
healthcare facilities, suggesting that time to presentation
and treatment may indeed be a key intervention point to
reduce mortality. Studies on tuberculosis and trypano-
somiasis in Africa have reported that delays in presenta-
tion to a healthcare facility were associated with many
factors, including sex, age, rurality, and socio-economic
status [11–13]. Informed by these studies and the three
delays model [14, 15], we hypothesised that similar fac-
tors play an important role in delayed presentation time
for people with LF.
To inform public health interventions including tar-
geted health education, risk communication and pre-
ventative measures, it is important to identify factors
that are associated with cases presenting later to health-
care facilities. We aimed to examine whether there are
demographic, exposure, or clinical factors associated
with delayed presentation of people with LF to a health-
care facility in Nigeria.
Methods
We undertook a retrospective cohort study of all labora-
tory confirmed LF cases reported through routine na-
tional outbreak surveillance data in Nigeria with onset
dates between December 2018 and April 2019.
Data collection and management
During this period, national routine surveillance for LF
comprised data from laboratory, case management (clin-
ical) and case investigation (epidemiological) forms. The
forms captured demographic information (age, sex, resi-
dential address, occupation), date of admission, hospital
name, clinical details (date of symptom onset, symp-
toms) and exposures (contact with known or suspected
LF case, being part of a contact tracing list, history of
travel, direct contact with rodents or rodent faeces and
urine, participation in burial activity).
The case management forms were completed at the
healthcare facility that the case presented to. Specimen
samples were tested at the laboratories at the Federal
Teaching Hospital Abakaliki (FETHA), Irrua Specialist
Teaching Hospital (ISTH), Lagos University Teaching
Hospital (LUTH), Federal medical Centre Owo LF La-
boratory and the National Reference Laboratory (NRL)
Gaduwa. Average turnaround time of the diagnostic re-
sults is 48 h, ranging between 24 to 96 h. Turnaround
time is largely dependent on the proximity of the state
to the testing laboratory. The testing laboratory and a
Local Government Area (LGA) Disease Surveillance and
Notification Officer or State Epidemiologist entered the
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data into a line list and/or in the Surveillance Outbreak
Response Management and Analysis System (SORMAS)
platform (implemented in 12 states). An LGA is an ad-
ministrative geographical division of a state. There are
774 LGAs across the 36 states of Nigeria and the Federal
Capital Territory (Fig. 1) [16]. The Nigeria Centre for
Disease Control managed and linked the data.
Data cleaning and analysis
Data were de-duplicated and anonymised in Stata 14.
Presentation time was defined as the difference, in days,
between date of symptom onset and date of presentation
at a healthcare facility. Considering biological plausibil-
ity, only those with a presentation time between 1 and
21 days were included.
Clinical symptoms were categorised as mild or severe
based on LF literature [17, 18]. If a case had mild and se-
vere symptoms, they would be categorised as severe if a
case had only mild symptoms they would be categorised
as mild. For example, headache, slight fever, general
malaise and weakness would be categorised as a mild
symptoms and haemorrhaging (in gums, eyes, or nose,
as examples), respiratory distress, repeated vomiting, fa-
cial swelling, pain in the chest, back, and abdomen, and
shock would be categorised as severe symptoms [17, 18].
Rurality of residence was based on the residential LGA
mapped to a rurality index table (rural, semi-urban and
urban) [19, 20]. Age data were grouped based on life
stages (0–4, 5–12, 13–17, 18–25, 26–59 and 60+ year-
olds). Sex and age-groups were looked at separately and
together.
Malaria is highly prevalent in some areas of Nigeria
and early symptoms of LF are similar (e.g. fever, head-
aches, vomiting) [21]. Understandably, people may in-
correctly assume early symptoms of LF are those of
malaria which may affect time to presentation. Malaria
prevalence category was based on the findings of the
Nigeria Malaria Indicator Survey (2015). We used the
prevalence in children as a proxy for malaria prevalence
in the cases’ state of residence [16].
To assess completeness, the proportion of missing data
was calculated. To determine if missing data were com-
pletely at random, a mixed effects logistical regression
for age-group and sex was undertaken.
Fig. 1 Map of Nigeria. Map produced by study authors on behalf of Nigeria Centre for Disease Control. FCT = Federal Capital Territory
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We described the time to presentation (range, inter-
quartile range, median time in days) and the number of
cases that attended a healthcare facility within 6 days or
less following symptom onset by demographic, clinical
and exposure factors. We undertook a univariate ana-
lysis using a Cox Proportional-Hazards regression model
to investigate the effect of each variable on the time to
presentation. The Proportional Hazard assumption was
tested on the basis of Schoenfeld residuals after fitting
the Cox regression model.
Characteristics of people attending healthcare facilities
in certain LGAs may be more similar e.g. a higher pro-
portion of farmers in more rural LGAs. We accounted
for LGA level clustering using a multi-level model to in-
clude the random effects of LGA to attending a health-
care facility.
For all models, 95% confidence intervals and p-values
were calculated using the Wald test. A multivariable
analysis was not performed following the univariate Cox
Proportional-Hazards analysis, as no variables had a p-
value of < 0.2, an a priori requirement.
Ethics
Ethical committee clearance was provided to undertake
this study which uses retrospective routine data collected




Of 499 confirmed LF cases in the dataset, 417 (84%) had
complete dates for symptom onset and attendance at a
healthcare facility. Of these, 389 (78% of all cases) had
presentation dates between 1 and 21 days, and thus com-
prised our dataset for analysis.
The median time to presentation to a healthcare facil-
ity was 6 days (Inter quartile range [IQR] 4–10 days),
with 53.4% attending in 6 days or less (Table 1). Males
and females had the same median time to presentation
(6 days).
By age-group only, median presentation time ranged
between 5 and 7 days with 45.2 to 71.0% of cases pre-
senting within 6 days of onset.
By sex, there were differences seen among the younger
age-groups, with 0–4 year-old females presenting earlier
than males (females: 4 days [IQR 3–7 days] and 73%,
males: 10 days [IQR 5–15] and 30%). For 5–12 and
13–17 year-olds, males had a shorter median presenta-
tion time and higher proportion presenting within 6
days of onset compared to females (males aged 5–12
years: 5 days [IQR 4–8], 65% and males aged 13–17
years: 3 days [IQR 3–6], 85%; females aged 5–12 years:
6 days [IQR 3–7], 50% and females aged 13–17: 5 days
[IQR 2–9], 61%).
Most cases in the dataset came from Edo (44.0%) and
Ondo (22.4%) States, who had median presentation
times of 6 days. The longest presentation times were
seen in Cross River (15 days) and Nasarawa (14.5 days,
[IQR 8–21]) but case numbers were small. Most cases
resided in rural areas (61.2%). Approximately 50% of
cases in each rurality index category attended within 6
days.
Cases living in areas with the lowest malaria preva-
lence category (0–11%) had the longest median presen-
tation time of 8 days (IQR 6–10) and 25% (1 case)
attended within 6 days.
By occupation, transporters (people who drive infor-
mal public transport vehicles) had the longest median
presentation time (9 days [IQR 7–10]) closely followed
by those not working/retired (8.5 days [IQR 3–12]).
Data for education status and symptoms were limited
(77.9 and 62.7% missing). Exposure data was poorly
completed (between 40.6 and 94.9% missing, with the
exception of travel history, for which only 6.2% were
missing). Where information was available for travel his-
tory, people who had a travel history had the same me-
dian time to presentation as those who did not have a
history of travel (6 days).
Missing data analysis
When comparing age groups for those with missing
presentation time to those without missing presentation
time, there was no statistical evidence of a difference (p-
value 0.77). When comparing by sex, there was evidence
of a difference, with females less likely to have missing
presentation times than males (odds ratio 0.57, 95%CI
0.34–0.95, p-value 0.03).
Univariate analysis
There was no statistically significant difference between
any variable with regard to time to presentation to a
healthcare facility (Table 2). The proportional hazard as-
sumption was met for all variables at the 5% significant
level.
Discussion
Multiple factors may contribute to a delayed presenta-
tion to a healthcare facility and seeking early treatment
and care for LF. This increases the likelihood of severe
illness and death. Our study showed that almost half of
all confirmed cases presented to a healthcare facility 6
days after symptom onset, but we did not find any spe-
cific factors statistically associated with delayed presenta-
tion of confirmed cases. This suggests that there is need
for more public health action and messaging around LF
and seeking healthcare.
We found that particular groups have longer median
presentation times or present less often within 6 days of
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Case definition number of cases Laboratory
Confirmed
389 208 (53.4) 6 4–10 1–21
Sex Female 181 (46.5) 101 (55.8) 6 3–10 1–21
Male 207 (53.2) 107 (51.7) 6 4–10 1–21
Unknown 1 (0.3) 0 7 n/a n/a
Age group (years) 0–4 21 (5.4) 11 (52.4) 6 4–13 1–16
5–12 35 (9.0) 20 (57.1) 6 4–9 1–21
13–17 31 (8.0) 22 (71.0) 5 2–8 1–21
18–25 56 (14.4) 33 (58.9) 6 3–10 1–21
26–59 214 (55.0) 107 (50.0) 6 4–10 1–21
60+ 31 (8.0) 14 (45.2) 7 3–10 1–14
Unknown 1 (0.3) 1 (100) 4 n/a n/a
Age group (years) and Sex (n = 387)
Males (n = 206) 0–4 10 (4.9) 3 (30.0) 10 5–15 3–16
5–12 17 (8.3) 11 (64.7) 5 4–8 1–20
13–17 13 (6.3) 11 (84.6) 3 3–6 2–21
18–25 27 (13.1) 16 (59.3) 6 3–10 1–16
26–59 123 (59.7) 59 (48.0) 7 5–10 1–21
60+ 16 (7.8) 6 (37.5) 7 2–10 1–14
Females (n = 181) 0–4 11 (6.1) 8 (72.7) 4 3–7 1–14
5–12 18 (9.9) 9 (50) 6 4–10 1–21
13–17 18 (9.9) 11 (61.1) 5 2–9 1–18
18–25 29 (16) 17 (58.6) 6 3–12 1–21
26–59 90 (49.7) 48 (53.3) 6 4–12 1–20
60+ 15 (8.3) 8 (53.3) 6 3–10 1–14
Mortality status outcome Alive 324 (83.3) 175 (54.0) 6 4–10 1–21
Deceased 65 (16.7) 33 (50.8) 6 3–10 1–19
State of residence Abia* 0 n/a n/a n/a n/a
Adamawa 0 n/a n/a n/a n/a
Akwa Ibom* 0 n/a n/a n/a n/a
Anambra* 0 n/a n/a n/a n/a
Bauchi 36 (9.3) 13 (36.1) 8 6–13 1–21
Bayelsa* 0 n/a n/a n/a n/a
Benue 4 (1.0) 1 (25.0) 8 6–10 5–11
Borno* 0 n/a n/a n/a n/a
Cross River 1 (0.3) 0 15 n/a n/a
Delta 2 (0.5) 0 13.5 13–14 13–14
Ebonyi 33 (8.5) 14 (42.4) 7 4–10 1–14
Edo 171 (44.0) 94 (55.0) 6 4–10 1–21
Enugu 0 n/a n/a n/a n/a
Ekiti* 0 n/a n/a n/a n/a
Federal
Capital
1 (0.3) 0 11 n/a n/a
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Gombe 1 (0.3) 1 (100) 4 n/a n/a
Imo 1 (0.3) 0 8 n/a n/a
Jigawa* 0 n/a n/a n/a n/a
Kaduna 3 (0.8) 2 (66.7) 5 3–20 3–20
Kano 0 n/a n/a n/a n/a
Katsina* 0 n/a n/a n/a n/a
Kebbi 1 (0.3) 1 (100) 3 n/a n/a
Kogi 2 (0.5) 0 10 8–12 8–12
Kwara 1 (0.3) 1 (100) 2 n/a n/a
Lagos* 0 n/a n/a n/a n/a
Nasarawa 2 (0.5) 0 14.5 8–21 8–21
Niger* 0 n/a n/a n/a n/a
Ogun* 0 n/a n/a n/a n/a
Ondo 87 (22.4) 58 (66.7) 6 3–7 1–20
Osun* 0 n/a n/a n/a n/a
Oyo 1 (0.3) 1 (100) 5 n/a n/a
Plateau 27 (6.9) 13 (48.2) 7 2–13 1–20
Rivers 1 (0.3) 1 (100) 4 n/a n/a
Sokoto* 0 n/a n/a n/a n/a
Taraba 14 (3.6) 8 (57.1) 6 5–14 2–20
Yobe* 0 n/a n/a n/a n/a
Zamfara* 0 n/a n/a n/a n/a
Rurality category (based on state of
residence and information from state
guidance)
Rural 238 (61.2) 124 (52.1) 6 4–11 1–21
Semi-urban 14 (3.6) 7 (50.0) 6.5 4–9 3–12
Urban 134 (34.4) 75 (56.0) 6 4–9 1–20
Unknown 3 (0.8) 2 (66.7) 4 1–15 1–15
Malaria Prevalence category 0–11% 4 (1.0) 1 (25.0) 8 6–10 4–12
12–21% 298 (76.6) 166 (55.7) 6 4–10 1–21
22–29% 3 (0.8) 2 (66.7) 4 2–15 2–15
30–36% 62 (15.9) 27 (43.55) 7 4–10 1–21
37–64% 22 (5.7) 12 (54.6) 7 5–11 2–20
Education status Primary 20 (5.1) 10 (50.0) 6.5 5–9.5 3–20
Secondary 32 (8.2) 19 (59.4) 5 3–9 1–15
Tertiary 35 (9.0) 17 (48.6) 7 3–10 1–20
Unknown 302 (77.6) 162 (53.6) 6 4–10 1–21
Occupation group Artisan 11 (2.8) 6 (54.6) 6 4–11 2–15
Business or
Professionala
101 (26.0) 45 (44.6) 7 4–11 1–20
Casual
Labourer
1 (0.3) 0 7 n/a n/a
Farmer 35 (9.0) 21 (60.0) 6 4–10 1–19
Health Worker 12 (3.1) 7 (58.3) 4.5 3.5–9.5 2–13
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symptom onset. Edo and Ondo states had a high num-
ber of cases captured within the surveillance system
compared to the other states but did not have the lon-
gest presentations delays. The shorter presentation times
in Edo and Ondo may be attributed to the historical
high incidence of LF in these states leading to a higher
index of suspicion and greater awareness among the
population. Areas such as Nasarawa and Cross Rivers
states, which had fewer cases but the longest presenta-
tion times, may benefit from more targeted risk commu-
nication and public health action. While the regression
analysis did not show any factors associated with later
















Housewife 32 (8.2) 14 (43.8) 7 5–13 1–21
Religious or
Traditionala




126 (32.4) 72 (57.1) 6 3–10 1–21
Transporter 5 (1.3) 1 (20.0) 9 7–10 4–15
Not working
or Retired
10 (2.6) 4 (40.0) 8.5 3–12 1–14
Unknown 50 (12.9) 36 (72.0) 6 3–7 1–21
Symptoms Mild 123 (31.6) 78 (63.4) 6 4–8 1–21
Severe 22 (5.7) 12 (54.6) 6 3–8 1–14
Unknown 244 (62.7) 118 (48.4) 7 4–11 1–21
First symptom Mild 167 (42.9) 83 (49.7) 7 4–11 1–21
Severe 2 (0.5) 1 (50.0) 8 2–14 2–14
Unknown 220 (56.6) 124 (56.4) 6 4–9.5 1–21
Exposure to confirmed case No 87 (22.4) 43 (49.4) 7 4–9 1–20
Yes 39 (10.0) 20 (51.3) 6 4–10 1–20
Unknown 263 (67.6) 145 (55.1) 6 4–10 1–21
Exposure to rodents No 8 (2.0) 2 (25.0) 9 6.5–16 3–20
Yes 12 (3.1) 4 (33.3) 8 6–12 2–20
Unknown 369 (94.9) 202 (54.7) 6 4–10 1–21
Part of a contact tracing list No 124 (31.4) 57 (46.0) 7 4.5–11 1–21
Yes 36 (9.8) 19 (52.8) 6 3.5–10 1–20
Unknown 229 (58.8) 132 (57.6) 6 3–10 1–21
History of travel No 279 (71.7) 148 (53.1) 6 4–10 1–21
Yes 86 (22.1) 48 (55.8) 6 4–11 1–20
Unknown 24 (6.2) 12 (50.0) 6.5 3–13.5 2–21
Attended a funeral No 230 (59.1) 124 (53.9) 6 3–10 1–21
Yes 1 (0.3) 0 11 n/a n/a
Unknown 158 (40.6) 84 (53.2) 6 5–10 1–21
Participated in a funeral (touched
body)
No 156 (40.1) 75 (48.1) 7 4–10 1–21
Yes 4 (1.0) 2 (50.0) 6 2–10 2–13
Unknown 229 (58.9) 131 (53.5) 6 4–10 1–21
Includes only those that have a non-missing value for the time to presentation variable and the characteristic and for presentation times between 1 and 21 days
a Business or professional: A business person here refers to one who earns profit by supplying goods and services while a professional refers to someone with
specified qualifications or expertise who gets paid for rendering services. Religious or Traditional: Traditional healers use indigenous plants, herbs and the root of
plants to heal sick people while religious healer use prayers predominantly to heal sick people
*No information for this state has been reported in this dataset
Chandra et al. BMC Infectious Diseases          (2021) 21:143 Page 7 of 11
Table 2 Cox univariate analysis of confirmed cases by demographic, clinical and exposure factors, Nigeria 2019, (n = 389)
Characteristic Stratum Hazard ratio Crude 95% CI Crude p-value Proportional Hazard
test of assumption
Sex Male Ref 0.97 0.28
Female 1.10 0.82–1.23
Age (per year) 1.00 0.99–1.01 0.95 0.05






Mortality status Dead Ref
Alive 0.97 0.73–1.28 0.81 0.45
Rurality Rural Ref 0.34 0.37
Semi-urban 1.39 0.79–2.46
Urban 1.15 0.89–1.49





Education status Primary Ref 0.38 0.97
Secondary 1.44 0.81–2.55
Tertiary 1.1 0.63–1.91
Occupation group Not working or retired Ref 0.95 0.65
Student or Child or Apprentice 1.13 0.57–2.23
Housewife 0.89 0.42–1.88
Farmer 1.21 0.58–2.54
Casual labourer 1.26 0.16–10.02
Transporter 0.91 0.30–2.72
Religious or Traditionala 1.45 0.51–4.10
Artisan 1.15 0.47–2.78
Business or Professionala 1.10 0.55–2.18
Health Worker 1.47 0.61–3.55
Symptom severity Mild Ref 0.90 0.61
Severe 1.03 0.65–1.63
Exposure to rodents No Ref 0.69 0.82
Yes 1.23 0.45–3.34
Exposure to confirmed case No Ref 0.77 0.93
Yes 0.94 0.64–1.38
History of Travel No Ref 0.76 0.26
Yes 1.04 0.81–1.34
Attended a funeral No Ref 0.79 0.35
Yes 0.65 0.09–4.68
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presentation, it is important to recognise that almost half
of the cases presented 6 days after symptom onset. There
may be a systemic reason for cases to present later
which may not be evident from this study.
The findings of the Cox regression are somewhat
unexpected, as other studies investigating health seek-
ing behaviours, delays in diagnostics and presentation
for other infectious and parasitic diseases have found
significant associations with various factors. Ukwaja
et al., 2013, found that factors associated with in-
creased presentation delay in Nigeria for tuberculosis
cases were older age, distance to a health facility and
urban residency [13]. However, a study by Hulland
et al., 2019 showed that in Nigeria, 98% of the popu-
lation at risk of VHFs had travel times to a health fa-
cility of under 2 h with exceptions of some states, so
this may not be a factor for delayed presentation for
LF [22]. In Zambia, Needham et al., 2001 found that
there were significant socio-demographic factors asso-
ciated with delay, including being female and only
having an education up to the age of 9 years [11]. For
Ebola disease, another VHF, Theocharopoulos et al.,
2017, found that transportation time and age affected
the time to admission for Ebola patients in Sierra
Leone [23]. A common practice in Nigeria, particu-
larly in Northern states, is for a woman to seek her
husband’s consent before going out therefore not see-
ing an association with sex and time to presentation
is unexpected [24].
We believe that our findings resulted in part from
limitations of the surveillance data, including a lack
of data from multiple years of outbreaks and high
quality and complete epidemiological and exposure
data. Education status was missing for almost 80% of
the confirmed cases in our dataset, with no option
provided for ‘no formal education’. Symptom data
were missing for more than 60% of cases and expos-
ure data was missing in up to 95% of cases. This
limits the interpretation of our findings and potential
interventions to be put into place. More years of sur-
veillance data, collected in a consistent manner with
higher completion rates for variables, may provide a
clearer picture of factors associated with presentation
delays, which may be important to inform public
health messaging.
Study limitations
Firstly, this analysis was restricted to confirmed case re-
cords that had completed symptom onset and healthcare
attendance dates (78% of confirmed cases); this may in-
crease the risk of selection bias limiting the generalis-
ability of the analysis. We compared cases with missing
presentation times by age and sex in a logistic regres-
sion. For age group, there was no significant difference
between those with and without presentation time, sug-
gesting that the dates may be missing completely at ran-
dom. However, for sex, there was a statistical difference,
with males more likely to have missing presentation
dates. Therefore, data may not be missing completely at
random and may have introduced bias into our results.
Secondly, the completion of symptom onset dates var-
ied across different LGA areas and/or health facilities.
We decided to exclude dates where presentation time
was 0 days or greater than 21 days. This may have ex-
cluded true data, but it is unlikely given the mild symp-
toms at onset and the likelihood of death or resolution
after 21 days. A presentation time of 0 could have oc-
curred if the case had known LF exposures or were part
of a contact tracing list; but these fields were poorly
completed.
Thirdly, underreporting in certain states may be an
issue, with several states reporting little or no cases,
which may not be a true indication of the incidence.
Finally, residual confounding could occur as only a few
variables are currently collected for establishing presen-
tation delay, which may limit interpretation of factors as-
sociated with delays.
Future work
To generate hypotheses, important gaps in LF surveil-
lance data need to be addressed across all states of
Nigeria. This requires a coordinated effort nationally
and regionally. Detailed and complete information needs
to be captured for clinical and exposure factors. This
work is currently ongoing in Nigeria with the complete
roll-out and use of the Surveillance Outbreak Response
Management and Analysis System (SORMAS), which
was partially rolled out at the time of this study (12
states). Further details around SORMAS are found else-
where [25]. With the wider use of SORMAS, the linked
electronic system allows improved data completion,
Table 2 Cox univariate analysis of confirmed cases by demographic, clinical and exposure factors, Nigeria 2019, (n = 389) (Continued)
Characteristic Stratum Hazard ratio Crude 95% CI Crude p-value Proportional Hazard
test of assumption
Participated in a funeral (touched body) No Ref 0.92 0.64
Yes 1.05 0.38–2.90
a Business or professional: A business person here refers to one who earns profit by supplying goods and services while a professional refers to someone with
specified qualifications or expertise who gets paid for rendering services. Religious or Traditional: Traditional healers use indigenous plants, herbs and the root of
plants to heal sick people while religious healer use prayers predominantly to heal sick people
Chandra et al. BMC Infectious Diseases          (2021) 21:143 Page 9 of 11
removes some of the traditional paper-based forms,
improving the data quality and removing duplication
of efforts. It is important that clear definitions are
used throughout the system and across states. Follow-
ing full implementation of SORMAS a detailed evalu-
ation would improve understanding of any regional
surveillance infrastructure issues or reporting biases.
This may help explain some surveillance artefacts,
such as high case numbers in some areas compared
to others, that could affect interpretation of studies
using this surveillance data. Further understanding
on an association with mortality and delayed presen-
tation would be worthwhile, which would require
complete follow-up information on mortality status
following confirmed LF diagnosis.
To reduce residual confounding, further data could be
collected on social and structural factors such as health
literacy level, homelessness, poverty, physical disability,
similar to McQuilkin et al., 2017 in Liberia during the
Ebola epidemic [26]. This will improve knowledge on
healthcare access issues and attitudes during outbreaks.
This may be difficult to establish and collect in routine
surveillance.
Further quantitative and qualitative studies should be
considered beyond routinely collected surveillance and
collect data underpinned by frameworks of delays, such
as the three-delays model [14, 15]. Adewole et al., 2017
collected data on other determinants of poor health
seeking behaviour such as out of pocket payment, health
insurance coverage and levels of self-treatment [27].
Although Hulland et al. [22] have done work in investi-
gating travel times to a healthcare facility, a useful en-
hancement would be to collect information on travel
time from residence to healthcare facility, to assess
accessibility.
It is important to recognise that risk factors may
change with time, so where plausible surveillance should
be updated to capture additional risk factors for
investigation.
Once outbreak surveillance data quality is improved
over a series of LF outbreak years, this study can be re-
peated to generate further hypotheses. This will allow
for targeted public health interventions such as educa-
tion and risk communication to reduce the mortality of
confirmed LF cases.
Conclusions
Whilst we observed important differences in presenta-
tion delays across factors, our study did not indicate a
statistical association of any routinely collected factors
with a delayed presentation of LF cases to a healthcare
facility. Such associations may exist, but incomplete rou-
tine outbreak surveillance data may have hampered our
ability to identify them. However, almost half of
confirmed LF cases presented after 6 days of symptom
onset, beyond the period in which ribavirin may be most
effective. This highlights a need for improved national
surveillance and studies to determine if there are sys-
temic or specific causes for delays for LF and potentially
other VHF cases. This information will help to inform,
monitor, strengthen and evaluate risk communication
and public health action strategies, to reduce the CFR
associated with delayed care and treatment of LF cases.
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